NCT03447600 (DIVA) is a NA clinical trial of Alternate Day Fasting in Overweight and Obesity, sponsored by University of Leeds.

Who is sponsoring NCT03447600?

NCT03447600 is sponsored by University of Leeds.

What drugs are being tested in NCT03447600?

Interventions in NCT03447600: Alternate Day Fasting, Continuous dietary restriction.

What condition does NCT03447600 study?

NCT03447600 studies Overweight and Obesity.

Is NCT03447600 still recruiting?

NCT03447600 is currently completed. Last updated 6 November 2020.

Last reviewed 2020-11-06 · How we verify

NCT03447600: DIVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diet-Induced Variability in Appetite (DIVA)

Completed NA Last updated 6 November 2020

What this trial tests

NA trial testing Alternate Day Fasting in Overweight and Obesity in 54 participants. Completed in 12 December 2018.

Timeline

1 March 2018

Primary endpoint
12 December 2018

12 December 2018

Quick facts

Lead sponsor	University of Leeds
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	54
Start date	1 March 2018
Primary completion	12 December 2018
Estimated completion	12 December 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

Alternate Day Fasting
Continuous dietary restriction

Conditions studied

Overweight and Obesity — all drugs for Overweight and Obesity →

Sponsor

University of Leeds

Who can join

Adults 18 to 55, female only, with Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to test the hypothesis that dietary weight loss (WL) through alternate day fasting (ADF) will enhance appetite control, health markers and wellbeing following WL compared to standard daily calorie restriction (CR).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Matched Weight Loss Through Intermittent or Continuous Energy Restriction Does Not Lead To Compensatory Increases in Appetite and Eating Behavior in a Randomized Controlled Trial in Women with Overweight and Obesity.
Beaulieu K, Casanova N, Oustric P, Turicchi J, et al · · 2020 · cited 56× · PMID 31825067 · DOI 10.1093/jn/nxz296
Effects of Intermittent Fasting in Human Compared to a Non-intervention Diet and Caloric Restriction: A Meta-Analysis of Randomized Controlled Trials.
Gu L, Fu R, Hong J, Ni H, et al · · 2022 · cited 38× · PMID 35586738 · DOI 10.3389/fnut.2022.871682
Food Liking but Not Wanting Decreases after Controlled Intermittent or Continuous Energy Restriction to ≥5% Weight Loss in Women with Overweight/Obesity.
Oustric P, Beaulieu K, Casanova N, O'Connor D, et al · · 2021 · cited 11× · PMID 33435287 · DOI 10.3390/nu13010182

Verify or expand the search:

Other trials of Alternate Day Fasting

Trials testing the same drug.

NCT04732130 — Monitoring During Different Intermittent Fasting Protocols in Non-Obese Adults · NA · completed
NCT03652532 — Alternate Day Fasting and Exercise in Overweight or Obese Adults · NA · completed

Other recruiting trials for Overweight and Obesity

Currently open trials in the same condition.

NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Other University of Leeds trials

Trials by the same sponsor.

NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins · NA · not yet recruiting
NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain · NA · not yet recruiting
NCT07247812 — tSCS in Children and Young People With HCP · NA · not yet recruiting
NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
NCT06240403 — Digoxin and Senolysis in Heart Failure and Diabetes Mellitus · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03447600 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leeds
Last refreshed: 6 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03447600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing